Inclusion Criteria:

          -  Patients must have a recurrent supratentorial WHO grade III or IV malignant glioma
             based on imaging studies;

          -  Prior histopathology consistent with a supratentorial WHO grade III or IV malignant
             glioma;

          -  Following biopsy, prior to administration of D2C7-IT, the presence of recurrent tumor
             must be confirmed by histopathological analysis;

          -  Age ≥ 18 years of age;

          -  Karnofsky Performance Status (KPS) ≥ 70%;

          -  Laboratory Values:

               -  Platelet Count ≥ 125,000 cells/mm3 prior to biopsy. Platelets ≥ 100,000 cells/mm3
                  prior to infusion;

               -  Hemoglobin ≥ 10 gm/dL prior to biopsy;

               -  Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 prior to biopsy;

               -  Serum creatinine ≤ 1.2 x the upper limit of normal (ULN) prior to biopsy;

               -  Liver Function: Total bilirubin ≤ 1.6 mg/dL prior to biopsy; AST/ALT ≤ 2.5 x the
                  ULN prior to biopsy;

               -  Prothrombin (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x upper
                  limit of normal (ULN) prior to biopsy. Patients with prior history of
                  thrombosis/embolism are allowed to be on anticoagulation, understanding that
                  anti-coagulation will be held in the peri-operative period per the neurosurgical
                  team's recommendations. Low molecular weight heparin (LMWH) is preferred. If a
                  patient is on warfarin, the international normalized ratio (INR) is to be
                  obtained and value should be below 2.0 prior to biopsy;

          -  Ability to comply with study and follow-up procedures;

               -  If the patient is a sexually active female of child bearing potential, whose
                  partner is male, or if the patient is a sexually active male, whose partner is a
                  female of child bearing potential, the patient must agree to use appropriate
                  contraceptive measures for the duration of the treatment of the tumor and for 6
                  months afterwards as stated in the informed consent. Female patients of child
                  bearing potential must have a negative serum pregnancy test at the time of
                  screening and within 48 hours of starting the D2C7-IT infusion

          -  Patients will sign an IRB-approved informed consent form prior to any study-related
             procedures.

          -  Able to undergo brain MRI with and without contrast.

        Exclusion Criteria:

          -  Prior, unrelated malignancy requiring current active treatment with the exception of
             cervical carcinoma in situ and adequately treated basal cell or squamous cell
             carcinoma of the skin;

          -  Pregnant or breastfeeding;

          -  Patients with contrast-enhancing tumor component crossing the midline, actively
             growing multi-focal tumor, infratentorial tumor or extensive tumor dissemination
             (subependymal or leptomeningeal);

          -  Patients with clinically significant increased intracranial pressure (e.g., impending
             herniation), uncontrolled seizures, or requirement for immediate palliative treatment;

          -  Patients with a known allergy to Gadolinium-DTPA;

          -  Unstable systemic disease in the opinion of the treating physician, for example active
             infection requiring IV antibiotics;

          -  Patients on greater than 4mg per day of dexamethasone within the 2 weeks prior to
             admission for D2C7-IT infusion;

          -  Patients with worsening steroid myopathy (history of gradual progression of bilateral
             proximal muscle weakness, and atrophy of proximal muscle groups);

          -  Less than 12 weeks from radiation therapy, unless progressive disease outside of the
             radiation field or 2 progressive scans at least 4 weeks apart or histopathologic
             confirmation;

          -  Treated with immunotherapeutic agents within 4 weeks before enrollment, unless the
             patient has recovered from the expected toxic effects of such therapy;

          -  Treated with antiangiogenic agents (like bevacizumab) within 4 weeks before biopsy;

          -  Treated with alkylating agents within 4 weeks before enrollment (6 weeks for
             nitrosoureas) or treated within 1 week before enrollment with daily or metronomic
             chemotherapy, unless the patient has recovered from the expected toxic effects of such
             therapy;

          -  Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless
             the patient has recovered from the expected toxic effects of such therapy.